Alshetaili Abdullah S, Almutairy Bjad K, Tiwari Roshan V, Morott Joseph T, Alshehri Sultan M, Feng Xin, Alsulays Bader B, Park Jun-Bom, Zhang Feng, Repka Michael A
Department of Pharmaceutics and Drug Delivery, Director, Pii Center for Pharmaceutical Technology, School of Pharmacy, The University of Mississippi, University, MS 38677, USA.
Curr Drug Deliv. 2016;13(5):730-41. doi: 10.2174/1567201812666151012113806.
Bitter tasting drugs represent a large portion of active pharmaceutical ingredients. Mini-tablets are specifically designed for patients with difficulty in swallowing particular in young children up to 10 years of age, geriatric patients and patients with esophagitis.
The present study was aimed to prepare, taste-masked mini-tablets, which are easily swallowed dosage forms, primarily to be used by pediatric and geriatric patients.
Ketoprofen (10%-50% w/w) and Eudragit® EPO were blended and extruded with a 5-mm strand die and cut into consistent mini-tablets by using an adapted downstream pelletizer.
Differential scanning calorimetry and polarized light microscopy-hot stage microscopy studies confirmed that the binary mixtures were miscible under the employed extrusion temperatures. In-vitro release studies showed that drug release was less than 0.5% within the first 2 min in simulated salivary fluid (pH 6.8) and more than 90% in the first 20 min in gastric media (pH 1.0). The results of the electronic tongue analysis were well correlated with the drug release profile of the mini-tablets in the artificial saliva. Scanning electron microscopy revealed no cracks on the surface of the minitablets, confirming that the mini-tablets were compact solids. Chemical imaging confirmed the uniform distribution of ketoprofen inside the polymer matrices.
Eudragit® EPO containing ketoprofen at various drug loads were successfully melt extruded into tastedmasked mini-tablets. The reduced drug release at salivary pH correlated well with Astree e-Tongue studies for taste masking efficiency.
苦味药物占活性药物成分的很大一部分。迷你片是专门为吞咽困难的患者设计的,特别是10岁以下的幼儿、老年患者和食管炎患者。
本研究旨在制备掩味迷你片,这是一种易于吞咽的剂型,主要供儿科和老年患者使用。
将酮洛芬(10%-50%w/w)和Eudragit®EPO混合,通过5毫米的模头挤出,并用改良的下游制粒机切成大小一致的迷你片。
差示扫描量热法和偏光显微镜-热台显微镜研究证实,二元混合物在所采用的挤出温度下是可混溶的。体外释放研究表明,在模拟唾液(pH 6.8)中,药物在前2分钟内的释放量小于0.5%,而在胃介质(pH 1.0)中,在前20分钟内的释放量超过90%。电子舌分析结果与迷你片在人工唾液中的药物释放曲线密切相关。扫描电子显微镜显示迷你片表面无裂缝,证实迷你片为致密固体。化学成像证实了酮洛芬在聚合物基质中的均匀分布。
成功地将含有不同药物载量酮洛芬的Eudragit®EPO熔融挤出成掩味迷你片。唾液pH值下药物释放的减少与Astree电子舌对掩味效率的研究结果密切相关。